Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Aptevo Therapeutics (APVO) Capital Expenditures (2016 - 2022)

Historic Capital Expenditures for Aptevo Therapeutics (APVO) over the last 7 years, with Q3 2022 value amounting to $4000.0.

  • Aptevo Therapeutics' Capital Expenditures fell 6923.08% to $4000.0 in Q3 2022 from the same period last year, while for Dec 2022 it was $135000.0, marking a year-over-year decrease of 8106.59%. This contributed to the annual value of $29000.0 for FY2022, which is 9593.27% down from last year.
  • Per Aptevo Therapeutics' latest filing, its Capital Expenditures stood at $4000.0 for Q3 2022, which was down 6923.08% from $118000.0 recorded in Q4 2021.
  • Over the past 5 years, Aptevo Therapeutics' Capital Expenditures peaked at $927000.0 during Q3 2018, and registered a low of $4000.0 during Q3 2022.
  • For the 4-year period, Aptevo Therapeutics' Capital Expenditures averaged around $315222.2, with its median value being $191000.0 (2021).
  • Its Capital Expenditures has fluctuated over the past 5 years, first soared by 58666.67% in 2018, then crashed by 6923.08% in 2022.
  • Quarter analysis of 4 years shows Aptevo Therapeutics' Capital Expenditures stood at $927000.0 in 2018, then tumbled by 83.5% to $153000.0 in 2019, then dropped by 22.88% to $118000.0 in 2021, then plummeted by 96.61% to $4000.0 in 2022.
  • Its Capital Expenditures was $4000.0 in Q3 2022, compared to $118000.0 in Q4 2021 and $13000.0 in Q3 2021.